| Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson’s disease A Parkhe, P Parekh, LV Nalla, N Sharma, M Sharma, A Gadepalli, A Kate, ... Neuroscience letters 716, 134652, 2020 | 44 | 2020 |
| Self-renewal signaling pathways in breast cancer stem cells LV Nalla, K Kalia, A Khairnar The International Journal of Biochemistry & Cell Biology 107, 140-153, 2019 | 32 | 2019 |
| WNT-β catenin signaling as a potential therapeutic target for neurodegenerative diseases: current status and future perspective K Ramakrishna, LV Nalla, D Naresh, K Venkateswarlu, MK Viswanadh, ... Diseases 11 (3), 89, 2023 | 26 | 2023 |
| mRNA-based vaccine for COVID-19: they are new but not unknown! VP Chavda, G Jogi, S Dave, BM Patel, L Vineela Nalla, K Koradia Vaccines 11 (3), 507, 2023 | 23 | 2023 |
| Advanced phytochemical-based nanocarrier systems for the treatment of breast cancer VP Chavda, LV Nalla, P Balar, R Bezbaruah, V Apostolopoulos, ... Cancers 15 (4), 1023, 2023 | 23 | 2023 |
| Pyruvate kinase M2: a metabolic bug in re-wiring the tumor microenvironment M Rihan, LV Nalla, A Dharavath, A Shard, K Kalia, A Khairnar Cancer Microenvironment 12 (2), 149-167, 2019 | 22 | 2019 |
| Association of COVID-19 with comorbidities: an update S Chatterjee, LV Nalla, M Sharma, N Sharma, AA Singh, FM Malim, ... ACS Pharmacology & Translational Science 6 (3), 334-354, 2023 | 21 | 2023 |
| Pyruvate kinase M2 in chronic inflammations: a potpourri of crucial protein–protein interactions S Patel, A Das, P Meshram, A Sharma, A Chowdhury, H Jariyal, A Datta, ... Cell biology and toxicology 37, 653-678, 2021 | 18 | 2021 |
| Boronic acid derivative activates pyruvate kinase M2 indispensable for redox metabolism in oral cancer cells M Rihan, LV Nalla, A Dharavath, S Patel, A Shard, A Khairnar Bioorganic & Medicinal Chemistry Letters 59, 128539, 2022 | 12 | 2022 |
| Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer LV Nalla, A Khairnar European Journal of Pharmacology 943, 175565, 2023 | 10 | 2023 |
| Targeting specificity protein 1 with miR-128-3p overcomes TGF-β1 mediated epithelial-mesenchymal transition in breast cancer: An in vitro study LV Nalla, P Gondaliya, K Kalia, A Khairnar Molecular Biology Reports 49 (7), 6987-6996, 2022 | 7 | 2022 |
| Phytochemical Loaded Nanovehicles of Biopolymer for Breast Cancer: A Systemic review VP Chavda, S Vuppu, R Bezbaruah, LV Nalla, SNR Gajula, PC Balar, ... Clinical Complementary Medicine and Pharmacology, 100114, 2023 | 4 | 2023 |
| Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors VP Chavda, PC Balar, LV Nalla, R Bezbaruah, NR Gogoi, SNR Gajula, ... ACS omega 8 (41), 37654-37684, 2023 | 3 | 2023 |
| Alpha mangostin inhibits proliferation, migration, and invasion of human breast cancer cells via STAT3 inhibition LV Nalla, A Dharavath, SK Behera, A Khairnar Advances in Cancer Biology-Metastasis 7, 100089, 2023 | 3 | 2023 |
| Fighting with brain-eating amoeba: challenges and new insights to open a road for the treatment of Naegleria fowleri infection SN Gajula, LV Nalla Expert Review of Anti-infective Therapy 21 (12), 1277-1279, 2023 | 1 | 2023 |
| An Amalgamation of Bioinformatics and Artificial Intelligence for COVID-19 Management: From Discovery to Clinic J Wang, V Chavda, R Prajapati, A Bedse, J Patel, S Popat, G Jogi, ... Current Research in Biotechnology, 100159, 2023 | 1 | 2023 |
| Small extracellular vesicle biomarkers in breast cancer: a real-time snapshot for early diagnosis and prognosis? SNR Gajula, LV Nalla Bioanalysis 15 (7), 367-370, 2023 | 1 | 2023 |
| Excipient toxicity and safety V Pandey, S Polaka, LV Nalla, M Tekade, MC Sharma, RK Tekade Pharmacokinetics and Toxicokinetic Considerations, 487-511, 2022 | 1 | 2022 |
| Nanoparticle‐Based mRNA Vaccines: Are We One Step Closer to Targeted Cancer Therapy? LV Nalla, SN Gajula, VP Chavda Nanocarrier Vaccines: Biopharmaceutics‐Based Fast Track Development, 275-303, 2024 | | 2024 |
| Socio-Economic and Environmental Impact of SARS-CoV-2 Variants A Hromić-Jahjefendić, VP Chavda, LV Nalla SARS-CoV-2 Variants and Global Population Vulnerability, 479-507, 2024 | | 2024 |
Amit KhairnarInternational Clinical Research Center, St Anne University Hospital, Brno, CZVerified email at fnusa.cz
